biological half-life

(redirected from Elimination half-life)
Also found in: Medical, Encyclopedia.

biological half-life

n.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
The observed elimination half-life was around 16-18 hours, offering potential for once daily dosing.
The elimination half-life (t1/2 [beta]) of a drug refers to the time required for a drug to be reduced to half of its original concentration in the body through various elimination processes.
The elimination half-life (2.4 hours) of cefixime in healthy young boys of aged 12-17 years old in present study was shorter than 5.0 and 4.7 hours,9 4.2 hours13 and 3.5 hours14 after oral administration of cefixime 400mg in healthy adult male subjects.
Because it has a uniquely long elimination half-life, it can be intravenously administered in one shot at 1500-mg dose.
In addition, NKTR-181 has a 14-hour elimination half-life to enable twice-daily dosing for pain control.
Diazepam has a long elimination half-life (20-100 hours), as does its active liver metabolite, nordiazepam (36-200 hours) (Greenblatt, Shader, Divoll & Harmatz, 1981), which means that therapeutic concentrations can be present for prolonged periods even after short-term treatments (Muzyk, Leung, Nelson, Embury & Jones, 2013).
Mean elimination half-life was 6.23 hours for the low dose and 7.84 hours for the high dose.
The terminal elimination half-life of lumbar epidural-administered triamcinolone in a noncompartmental analysis was 523 hours, and the peak triamcinolone concentration of 4.1 ng/mL was detected within 24 hours after administration.
However, the elimination half-life of [C.sub.8] PFPA that we report is 0.95 [+ or -] 0 .17 d, compared with the 1.6 [+ or -] 0.1 d reported for male rats by D'eon and Mabury (2010).
Although the estimated elimination half-life is long (about 11 days with a range of 6-24 days), the high molecular weight (about 154,000) should limit fetal exposure, at least in the first half of pregnancy The drug should be avoided in pregnancy, however, based on the animal data, the mechanism of action, and its combination with doxorubicin.
The elimination half-life (1,444.90 hr) observed in animals treated with the IM-DQ microsuspension was 1.92-fold longer compared to the half-life (751.01 hr) observed in mice treated with the IM-DQ nanosuspension (Table 2), suggesting the large DQ particle size significantly prolonged the half-life decoquinate.

Full browser ?